Article
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
Blood - 12 Mar 2020
DiNardo C D, Tiong I S, Quaglieri A, MacRaild S, Loghavi S, Brown F C, Thijssen R, Pomilio G, Ivey A, Salmon J M, Glytsou C, Fleming S A, Zhang Q, Ma H, Patel K P, Kornblau S M, Xu Z, Chua C C, Chen Xufeng, Blombery P, Flensburg C, Cummings N, Aifantis I, Kantarjian H, Huang D C S, Roberts A W, Majewski I J, Konopleva M, Wei A H
Abstract excerpt
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based combinations to identify molecular correlates of durable remission, response followed by relapse (adaptive resistance), or refractory disease (primary resistance). High...
Topics
- Age Factors
- Aged
- Aged, 80 and over
- Alleles
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Bridged Bicyclo Compounds, Heterocyclic
- Computational Biology